Independent validation of a model to predict early favorable PSA response (NADIR model) in enzalutamide-treated patients of the ARCHES trial.
Year: 2026
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Soumyajit Roy, Samuel Lichtman-Mikol, Andrew J. Armstrong, Neeraj Agarwal, Jorge A. Garcia, Angela Y. Jia, Rana R. McKay, Jason Robert Brown, Spyridon P. Basourakos, Iris Yeong- Fung Sheng, Amar Upadhyaya Kishan, Pedro C. Barata, Jonathan Evan Shoag, Nicholas G. Zaorsky, Scott C. Morgan, Christopher J.D. Wallis, Fred Saad, Neal D. Shore, Yilun Sun, Daniel Eidelberg Spratt
Institutions: University Hospitals Seidman Cancer Center, Case Western Reserve University, Case Comprehensive Cancer Center, Duke Medical Center, Duke Cancer Institute, University of Utah, Huntsman Cancer Institute, University Hospitals Cleveland Medical Center, Moores Cancer Center, University of California, Los Angeles, University Hospitals of Cleveland, Ottawa Hospital Foundation, University Health Network, University of Toronto, Princess Margaret Cancer Centre, Centre Hospitalier de l’Université de Montréal, Université de Montréal, Carolina Urologic Research Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7162500292
Cites:
Cited by:
Related to: